Acknowledgment
We thank Meghan Marino for assisting with identifying patients who underwent genetic testing at the Cole Eye Institute.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Funding
Grant Support: NIH/NEI K23-EY022947-01A1 (JPE); Ohio Department of Development TECH-13-059 (JPE); Foundation Fighting Blindness (EIT, JPE); and Research to Prevent Blindness (Cole Eye Institutional).
Financial Disclosures: GT: None; EIT: Sanofi (C), Retrophin (C), Sparks Therapeutics (C); JPE: Bioptigen (P, C), Synergetics (P), Leica (C), Zeiss (C), Thrombogenics (C, R); Genentech (R); Regeneron (R); Santen (C).